Abstract
An association between thrombotic thrombocytopenic purpura (TTP) and Sjögren’s syndrome (SS) is rare. This is the first report of two patients with TTP who had inhibitory autoantibodies to ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) complicating primary SS. A rapid diagnosis of TTP, which is a potentially lethal condition, made it possible to treat the two cases successfully. Only eight similar cases with TTP complicating SS have been reported in the literature. The possible presentation of primary SS without classic sicca symptoms, but with haematological abnormalities including TTP, should be recognised. Furthermore, it is important to measure ADAMTS13 activity and anti-ADAMTS13 antibodies, because TTP with SS seems to be a concurrent overlapping autoimmune disorder. We suggest that plasma exchanges in combination with corticosteroids should be administered as early as possible, since they appeared to be effective in treating TTP with SS, including in our cases.
Similar content being viewed by others
References
Remuzzi G. HUS and TTP. Variable expression of a single entity. Kidney Int. 1987;32:292–308.
Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662.
Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106:11.
Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995;48:2.
Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998;57:293.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585.
Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488.
Licht C, Stapenhorst L, Simon T, et al. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int. 2004;66:955.
Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043.
Rieger M, Mannucci PM. Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262.
Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64:347.
Theander E, Jacobsson LT. Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am. 2008;34:935.
Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood. 1992;80:1890–5.
Kasper CK, Pool JG. Letter: measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh. 1975;34:875–6.
Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–52.
Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta. 2005;357:17–33.
Parker Levine S. Thrombotic thrombocytopenic purpura and other forms of nonimmunologic platelet destruction. In: Wintrobe’s clinical hematology, 10th ed. Baltimore: Williams & Wilkins; 1999. p. 1612–22.
Caramaschi P, Riccetti MM, Pasini AF, et al. Systemic lupus erythematosus and thrombotic thrombocytopenia purpura. Report of three cases and review of the literature. Lupus. 1998;7:37–41.
Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenia purpura in childhood. Arthritis Rheum. 1999;42:2346–55.
Towheed TE, Anastassiades TP, Ford SE, Ford PM, Lee P. Thrombotic thrombocytopenic purpura as an initial presentation of limited systemic sclerosis. J Rheumatol. 1999;26:1613–6.
Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500.
Koga T, Yamasaki S, Nakamura H, Kawakami A, Furusu A, Taguchi T, Eguchi K. Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren’s syndrome complicated with IgM monoclonal gammopathy of undetermined significance. Rheumatol Int. 2010. (Epub ahead of print).
Schattner A, Friedman J, Klepfish A. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjögren’s syndrome. Clin Rheumatol. 2002;21:57–9.
Settefrati N, Bonomini M, Lodi M, D’Andrea T, Angelone A, Amoroso L, Palmieri PF, Albertazzi A. Sjögren’s syndrome associated with haemolytic-uraemic syndrome as the presenting clinical manifestation. Nephrol Dial Transpl. 1996;11:2316–9.
Abe H, Tsuboi N, Yukawa S, Tsuji S, Hayashi H, Yukawa N, Takanashi H, Tahara K, Tonozuka N, Hayashi T. Thrombotic thrombocytopenic purpura complicating Sjögren’s syndrome with crescentic glomerulonephritis and membranous nephritis. Mod Rheumatol. 2004;14:174–8.
Campbell GN, Gallo JH. Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjögren’s syndrome. Aust N Z J Med. 1998;28:214.
Noda M, Kitagawa M, Tomoda F, Iida H. Thrombotic thrombocytopenic purpura as a complicating factor in a case of polymyositis and Sjögren’s syndrome. Am J Clin Pathol. 1990;94:217–21.
Steinberg AD, Green WT Jr, Talal N. Thrombotic thrombocytopenic purpura complicating Sjögren’s syndrome. JAMA. 1971;215:757–61.
Agapitos E, Pavlopoulos PM, Vaiopoulos G, Davaris P. Primary Sjögren’s syndrome complicated by hemolytic uremic syndrome. Scand J Rheumatol. 1996;25:263–5.
George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927.
Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043.
Eknoyan G, Riggs SA. Renal involvement in patients with thrombotic thrombocytopenic purpura. Am J Nephrol. 1986;6:117.
Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int. 1991;39:811.
Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood. 1982;60:1030–7.
Feldman JD, Mardiney MR, Unanue ER, Cutting H. The vascular pathology of thrombotic thrombocytopenic purpura: an immunohistochemical and ultrastructural study. Lab Invest. 1966;15:927–46.
Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathy. In: Tisher CC, Brenner BM, editors. Renal pathology: with clinical and functional correlations. 2nd ed. Philadelphia: Lippincott; 1994. p. 1162–4.
Kaufman I, Schwartz D, Caspi D, Paran D. Sjögren’s syndrome—not just Sicca: renal involvement in Sjögren’s syndrome. Scand J Rheumatol. 2008;37:213–8.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yamashita, H., Takahashi, Y., Kaneko, H. et al. Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjögren’s syndrome: two cases and a literature review. Mod Rheumatol 23, 365–373 (2013). https://doi.org/10.1007/s10165-012-0644-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-012-0644-7